"Today, the U.S. Food and Drug Administration approved Kanuma (sebelipase alfa) as the first treatment for patients with a rare disease known as lysosomal acid lipase (LAL) deficiency.
Patients with LAL deficiency (also known as Wolman disea"...
Those normally associated with the surgical procedure being performed.
Postoperative intraocular pressure may also be elevated as a result of preexisting glaucoma, compromised outflow and by operative procedures and sequelae thereto, including enzymatic zonulysis, absence of an iridectomy, trauma to filtration structures, and by blood and lenticular remnants in the anterior chamber. Since the exact role of these factors is difficult to predict in any individual case, the following precautions are recommended:
- Don’t overfill the eye chambers with the Healon OVD (except in glaucoma surgery - See Applications section).
- In posterior segment procedures in aphakic diabetic patients special care should be exercised to avoid using large amounts of the Healon OVD.
- Remove some of the Healon OVD by irrigation and/or aspiration at the close of surgery (except in glaucoma surgery - See Applications section).
- Carefully monitor the intraocular pressure, especially during the immediate postoperative period. If significant rises are observed, treat with appropriate therapy.
Care should be taken to avoid trapping air bubbles behind the Healon OVD.
Because the Healon OVD is a highly purified fraction extracted from avian tissues and is known to contain minute amounts of protein, the physician should be aware of potential risks of the type that can occur with the injection of any biological material.
Because of reports of an occasional release of minute rubber particles, presumably formed when the diaphragm is punctured, the physician should be aware of this potential problem. Express a small amount of the Healon OVD from the syringe prior to use, and carefully examine the remainder as it is injected.
Reprocessed cannulas should not be used.
Sporadic reports have been received indicating that the Healon OVD may become ”cloudy” or form a slight precipitate following instillation into the eye.The clinical significance of these reports, if any, is not known since the majority received to date do not indicate any harmful effects on ocular tissues.The physician should be aware of this phenomenon and, should it be observed, remove the cloudy or precipitated material by irrigation and/or aspiration.
In vitro laboratory studies suggest that this phenomenon may be related to interactions with certain concomitantly administered ophthalmic medications.
Use only if solution is clear.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 8/16/2016
Additional Healon Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.